Pentixapharm Refocuses Strategy and Reduces Costs

Pentixapharm Holding AG has announced strategic changes to focus on its advanced clinical development programs, notably reducing early-stage research activities. The decision aligns with the company's strategy to prioritize high-value development projects, as outlined in May 2025. This move will see a 50% workforce reduction, aimed at decreasing operational costs and extending the financial runway into the first quarter of 2027.

The Berlin-based biotech firm, known for its work on novel radiopharmaceuticals, will concentrate resources on its pivotal Phase 3-ready CXCR4 program. This program targets the enhanced diagnosis of treatment-resistant hypertension, central to Pentixapharm’s clinical expertise.

CEO Dr. Dirk Pleimes explained that the adjustments will bolster the company's efficiency and ensure sustained growth while carefully managing the transition for affected employees.